These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Experience with the thyroid antagonist favistan]. KLEINDL K. Med Klin; 1955 Apr 15; 50(15):672-4. PubMed ID: 14383176 [No Abstract] [Full Text] [Related]
4. Variations in the response of individuals of different ages to an antithyroid compound (methimazole). McGAVACK TH, CHEVALLEY J, PEARSON S. J Am Geriatr Soc; 1955 Feb 15; 3(2):96-105. PubMed ID: 14353621 [No Abstract] [Full Text] [Related]
6. [Treatment of hyperthyroidism with 1-methyl-2-mercaptoimidazole]. KLEIN E, WIEDENMANN U. Dtsch Med Wochenschr; 1953 Jun 12; 78(24):877-8. PubMed ID: 13068021 [No Abstract] [Full Text] [Related]
11. [Clinical experiences with 1-methyl-2-mercaptoimidazole in the treatment of thyrotoxicosis]. KILPINEN O. Duodecim; 1952 Apr 23; 68(11):967-71. PubMed ID: 13033768 [No Abstract] [Full Text] [Related]
12. [Effectiveness of mercazolyl in thyrotoxicosis]. BARBA EI. Probl Endokrinol Gormonoter; 1957 Apr 23; 3(6):99-101. PubMed ID: 13527468 [No Abstract] [Full Text] [Related]
18. [Our experiences with ambulatory therapy of hyperthyroidism with favistan]. LEVNTAL Z, PUTNIK M, GLIGOROVA N. Med Glas; 1960 Feb 30; 14():140-3. PubMed ID: 14416352 [No Abstract] [Full Text] [Related]
19. Subclinical hyperthyroidism. Parker L. N Engl J Med; 2002 Jan 03; 346(1):67-8. PubMed ID: 11778009 [No Abstract] [Full Text] [Related]